Matches in DBpedia 2016-04 for { <http://dbpedia.org/resource/Celacade> ?p ?o }
Showing triples 1 to 38 of
38
with 100 triples per page.
- Celacade abstract "Celacade is a non-pharmacological treatment also known as Immune Modulation Therapy (IMT), developed by the Canadian based biotherapeutics company Vasogen, for treatment of chronic heart failure and peripheral artery disease. At the World Congress of Cardiology in September 2006 the Advanced Chronic Heart Failure Clinical Assessment of Immune Modulation Therapy (ACCLAIM) a phase III randomized, double-blind, placebo-controlled clinical trial involving some 2408 patients in 7 countries with left ventricular ejection fraction of 30% or less, reported that patients with a previous cardiovascular event receiving celacade where 39% less likely to die or be hospitalized due to a heart attack or stroke and tended to have improved quality of life. Celacade is believed to inhibit inflammation, platelet aggregation and progression of arterial lesions by a mechanism independent of cholesterol lowering. Celcade is a device-based outpatient procedure involving ex vivo exposure of 10ml autologous blood to heat, ultraviolet irradiation, controlled oxidative ozone therapy and subsequent intramuscular administration at monthly intervals. The results of ACCLAIM support the hypothesis that immune dysfunction plays a role in the pathogenesis of atherosclerosis and Immune Modulation therapy has a broad-spectrum positive effect on a number of immune mediators, including regulation and enhancement of cytokines and the vascular dilator nitric oxide. These cell signaling molecules regulate inflammation and facilitate the healing process. Vasogen in collaboration with Grupo Ferrer Internacional has regulatory approval to market Celacade as a medical device for the treatment of chronic heart failure in the European Union and Latin America.In the United States the Food and Drug Administration (FDA) has recommended that Vasogen conduct a further confirmatory study to support a pre-market approval filing.".
- Celacade wikiPageExternalLink immune.
- Celacade wikiPageID "6877491".
- Celacade wikiPageLength "5963".
- Celacade wikiPageOutDegree "19".
- Celacade wikiPageRevisionID "700260310".
- Celacade wikiPageWikiLink Atherosclerosis.
- Celacade wikiPageWikiLink Autotransplantation.
- Celacade wikiPageWikiLink Cardiology.
- Celacade wikiPageWikiLink Category:Medical_treatments.
- Celacade wikiPageWikiLink Cell_signaling.
- Celacade wikiPageWikiLink Cholesterol.
- Celacade wikiPageWikiLink Clinical_trial.
- Celacade wikiPageWikiLink Cytokine.
- Celacade wikiPageWikiLink Ejection_fraction.
- Celacade wikiPageWikiLink European_Union.
- Celacade wikiPageWikiLink Ex_vivo.
- Celacade wikiPageWikiLink Food_and_Drug_Administration.
- Celacade wikiPageWikiLink Heart_failure.
- Celacade wikiPageWikiLink Hypothesis.
- Celacade wikiPageWikiLink Immunity_(medical).
- Celacade wikiPageWikiLink Inflammation.
- Celacade wikiPageWikiLink Nitric_oxide.
- Celacade wikiPageWikiLink Ozone_therapy.
- Celacade wikiPageWikiLink Peripheral_artery_disease.
- Celacade wikiPageUsesTemplate Template:Notability.
- Celacade wikiPageUsesTemplate Template:Primary_sources.
- Celacade wikiPageUsesTemplate Template:Treatment-stub.
- Celacade subject Category:Medical_treatments.
- Celacade hypernym Treatment.
- Celacade type Drug.
- Celacade comment "Celacade is a non-pharmacological treatment also known as Immune Modulation Therapy (IMT), developed by the Canadian based biotherapeutics company Vasogen, for treatment of chronic heart failure and peripheral artery disease.".
- Celacade label "Celacade".
- Celacade sameAs Q5057415.
- Celacade sameAs m.0gtw_3.
- Celacade sameAs Q5057415.
- Celacade wasDerivedFrom Celacade?oldid=700260310.
- Celacade isPrimaryTopicOf Celacade.